Found 797 articles
Aadi Bioscience Announces Poster Presentations at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Aadi Bioscience, Inc. (NASDAQ: AADI) today announced that four abstracts have been selected for presentation at the upcoming 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, taking place October 11-15, 2023 in Boston, MA.
Telo Genomics Achieves Noteworthy International Standards Organization ("ISO") Regulatory Accreditation
Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo") is proud to announce that it has successfully completed the final assessment and achieved ISO 15189 accreditation. ISO 15189 is the international standard specific for clinical laboratories.
Nuvectis Pharma to Host KOL Event to Discuss Its Two Precision Medicine Clinical-Stage Drug Candidates, NXP800 and NXP900Virtual Event to be held on Thursday, September 14, 2023 at 10:00 a.m. ET
Nuvectis Pharma, Inc. today announced it will host a virtual KOL event to discuss its two clinical-stage drug candidates, NXP800 and NXP900, on Thursday, September 14, 2023 at 10:00am ET.
Watchmaker Genomics Announces Co-Exclusive License to Disruptive DNA Methylation Technology and Strategic Supply Agreements with Exact Sciences
Agreements Will Help Drive Greater Accuracy of Epigenetic Information for the Early Detection of Cancer
The global liquid biopsy market is evaluated at USD 4,722.73 million for the year 2022 and is projected to grow at a CAGR of 14.5% to reach a market size of USD 18,280.13 million by the year 2032, study published by Towards Healthcare.
FYR Diagnostics , an emerging company developing liquid biopsy technologies for the diagnosis of cancer and neurodegenerative diseases, is pleased to welcome Dr. Niall Lennon and Dr. Ryan Walters to its Scientific Advisory Board (SAB).
Children’s Hospital Los Angeles Researcher to Lead First-Ever International Liquid Biopsy Retinoblastoma Study
Recently, a researcher at Children’s Hospital Los Angeles developed a new way to diagnose retinoblastoma by sampling the fluid at the front of the eye.
MetaSight Diagnostics Emerges from Stealth and Announces Partnership with Maccabi's KSM Research and Innovation Center to Conduct Extensive Metabolomics Research
MetaSight Diagnostics announced their Israeli Multi-Omics Serum Screening study in collaboration with Kahn-Sagol-Maccabi, the Research and Innovation Center of Maccabi Health Services, Israel's leading HMO, has reached a new milestone: the creation of the a comprehensive metabolomics research consisting of hundreds of thousands of de-identified serum samples.
TellBio Announces Consecutive Manuscripts Showcasing Promising Translational and Clinical Applications of the TellDx Platform in Prostate Cancer and Tailoring Therapy in Advanced Breast Cancer
TellBio, Inc., a development stage biotechnology company focused on revolutionizing detection of cancer through its unique and proprietary circulating tumor cell (CTC) technology, the TellDx System, announces two publications that demonstrate the utility of CTC molecular analyses in patients with prostate cancer or advanced breast cancer.
INOVIQ and Promega Announce Global Joint Marketing Agreement for EXO-NET Exosome Isolation and Nucleic Acid Purification Solutions
INOVIQ and Promega sign a global joint marketing agreement for INOVIQ’s EXO-NET® exosome capture technology and Promega Nucleic Acid purification systems.
Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "TELO") announces that it has entered into an agreement with Leede Jones Gable Inc.
Ribbon Biolabs, the DNA synthesis company, announced the appointment of Roopom Banerjee as Executive Chairman of its Board of Directors.
Telo Genomics Presents Positive Data in Newly Diagnosed Multiple Myeloma Drug Resistance Study at EHA 2023
Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo") presented the results of its latest study on Friday June 09, 2023 at the European Hematology Association (EHA) 2023 annual meeting.
Toronto, Ontario--(Newsfile Corp. - June 14, 2023) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo") announces that it has closed its previously announced non-brokered private placement ("Offering") of units (the "Units").
Genomill and Finland's Cancer Research Flagship iCAN Partner To Improve Cancer Detection Using an Extensive Biobank Cohort
Genomill and iCAN, the Finnish national cancer research flagship project, signed a partnership aiming to improve the detection of trace tumour DNA from thousands of biobank samples.
U.S. Food and Drug Administration (FDA) Approves FoundationOne®Liquid CDx as a Companion Diagnostic for Pfizer’s BRAFTOVI® (encorafenib)
U.S. Food and Drug Administration (FDA) Approves FoundationOne ® Liquid CDx as a Companion Diagnostic for Pfizer’s BRAFTOVI® (encorafenib) in Combination With Cetuximab to Identify Patients With BRAF V600E Alterations in Metastatic Colorectal Cancer.
Repare Therapeutics Announces Publication in Nature Medicine Highlighting Clinical Benefit of Camonsertib in Advanced Solid Tumors
Repare Therapeutics Announces Publication in Nature Medicine Highlighting Clinical Benefit of Camonsertib in Advanced Solid Tumors.
Telo Genomics Announces Private Placement Increased to $2,766,375 from Previously Announced Private Placement of $2,000,000
Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "TELO") is pleased to announce that it has increased the size of its previously announced non-brokered private placement ("Offering") from up to $2 million in proceeds to $2,766,375 and 11,065,500 units (the "Units" or each a "Unit").
NeoGenomics and German Breast Group Announce New Data Demonstrating Clinical Potential of the RaDaR MRD Assay in HR+/HER2- Breast Cancer
NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology testing and global contract research services, today announced new data in support of its RaDaR assay for the detection of molecular residual disease (MRD) and recurrence in patients with high-risk hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer.
Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo") is excited to announce that the results of its smoldering multiple myeloma (SMM) studies that were conducted in collaboration with the Mayo Clinic were presented earlier today at the American Society of Clinical Oncology (ASCO) 2023 annual meeting.